Kopran Ltd

Kopran Ltd share price ticked higher by 1.17% to Rs 242.1 after the company's net profit plunged by 34.48% to Rs 4.39 crore, while revenue from operations gained significantly 37.19% to Rs 211.26 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, rising 5.09%. It has marginally improved by 2.16% over last one week and moved up slightly by 0.86% in last one month while the market capitalization of Kopran Ltd has softened by 3.04% and 23.72% in the same period respectively. Profit before tax (PBT) of Kopran Ltd stood at Rs 5.89 crore in Q3 FY26, nosediving by 150.64% year-on-year, and crashing by 33.07% quarter-on-quarter. EBITDA came in at Rs 15 crore, plunging by 378.53% YoY and easing 7.56% sequentially. Total expenses witnessed a sharp rise of 40.14% to Rs 201.74 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 136.03 crore, advancing by 12.52% YoY, while employee benefits expense was at Rs 20.18 crore, registering a growth of 9.32% YoY. For the TTM ended FY26, revenue from operations grew marginally by 8.23% to Rs 681.42 crore, while net profit tumbled by 33.26% to Rs 25.73 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 6980% to Rs 61.6 crore, and PBT tanked by 33.86% to Rs 34.36 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 66.75 crore in FY26, as against Rs 41.94 crore in FY25. Kopran Ltd rallied 46.02% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 9.87% during the same period.

Kopran Limited will hold a board meeting on Tuesday, November 3, 2026, at its registered office to consider and approve the unaudited standalone and consolidated financial results for the second quarter ended September 30, 2026, according to a regulatory filing with the Bombay Stock Exchange and the National Stock Exchange of India.

Kopran Limited confirmed compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, according to a certificate issued October 6, 2026. The confirmation, based on information received from Bigshare Services Pvt. Ltd., the company’s registrar and share transfer agent, stated that securities received for dematerialization were confirmed and that security certificates were mutilated and cancelled after verification by the depository participant.

Kopran Limited informed the Bombay Stock Exchange and the National Stock Exchange of India that the trading window for its directors, designated persons, and their immediate relatives will be closed from October 1, 2026, until forty-eight hours after the declaration of the company’s unaudited financial results for the second quarter ended September 30, 2026, in compliance with the Securities & Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015.

Kopran Limited informed the BSE Limited and National Stock Exchange of India Ltd. that its Corporate Affairs Committee approved the allotment of 40,500 equity shares to eligible employees upon exercise of options under the Kopran Employee Stock Option Plan 2023 (“ESOP 2023”/ “Plan”), with an exercise price of Rs 179 per share. Consequently, the company's paid-up equity share capital increased from Rs 482,856,050 to Rs 483,261,050, representing 48,326,105 equity shares.

Kopran Ltd share price softened by 2.78% to Rs 190.4 after the company's net profit plunged by 64.49% to Rs 6.7 crore, while revenue from operations nosedived 34.20% to Rs 153.99 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, easing 5.32%. It has inched up 0.53% over last one week and climbed by 11.64% in last one month while the market capitalization of Kopran Ltd has eased by 0.76% and 17.97% in the same period respectively. Profit before tax (PBT) of Kopran Ltd stood at Rs 8.8 crore in Q2 FY26, retreating 11.02% year-on-year, and plunging by 65.29% quarter-on-quarter. EBITDA came in at Rs 14 crore, rallying 18.84% YoY and tumbling by 58.16% sequentially. Total expenses saw a steep drop of 29.98% to Rs 143.96 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 120.89 crore, falling by 13.61% YoY, while employee benefits expense was at Rs 18.46 crore, jumping 12.15% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 8.23% to Rs 681.42 crore, while net profit tanked by 33.26% to Rs 25.73 crore, compared to previous TTM. EBITDA jumped by 6980% to Rs 61.6 crore, and PBT collapsed by 33.86% to Rs 34.36 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 66.75 crore in FY26, as against Rs 41.94 crore in FY25. Kopran Ltd surged by 20.20% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 1.97% during the same period.

Kopran will hold a meeting of the Board of Directors of the Company on 7 August 2026.

Kopran announced that the Annual General Meeting(AGM) of the company will be held on 18 August 2026.

Net profit of Kopran rose 94.94% to Rs 18.87 crore in the quarter ended March 2026 as against Rs 9.68 crore during the previous quarter ended March 2025. Sales rose 35.77% to Rs 234.02 crore in the quarter ended March 2026 as against Rs 172.36 crore during the previous quarter ended March 2025. For the full year,net profit declined 33.26% to Rs 25.73 crore in the year ended March 2026 as against Rs 38.55 crore during the previous year ended March 2025. Sales rose 8.23% to Rs 681.42 crore in the year ended March 2026 as against Rs 629.60 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales234.02172.36 36 681.42629.60 8 OPM %14.089.92 -9.0911.58 - PBDT29.8617.58 70 51.8367.54 -23 PBT25.3513.71 85 34.3651.95 -34 NP18.879.68 95 25.7338.55 -33 Powered by Capital Market - Live

Kopran announced that the Board of Directors of the Company at its meeting held on 19 May 2026, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 30%) , subject to the approval of the shareholders.